O'Shaugnessy 2005.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 100, breast cancer (stage I, II, IIIB); concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = 40000 IU sc weekly hb‐target = 13‐15 g/dL planned ESA duration = during chemotherapy
Outcomes	Primary: cognitive function, fatigue; secondary: QoL
Notes	study number = 40730
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	computer generated
Allocation concealment?	Low risk	coded drug packs of identical appearance